Haemonetics director Charles Dockendorff will not stand for re-election at 2026 annual meeting

HAEMONETICS CORP

Charles J. Dockendorff, Board member since 2014, will not stand for re-election at the 2026 Annual Meeting.
He serves on the Audit Committee and the Governance and Compliance Committee.
His decision is not the result of any disagreement with the company.
He will continue as a director and in his committee roles until the 2026 Annual Meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charles J. Dockendorff

Director

HAE · HAEMONETICS CORP

Filed: May 1, 2026, 7:59 PM ET

On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles J. Dockendorff departed as Director at HAEMONETICS CORP.

Action: will not stand for re-election
Role: Director

Exact text from the filing

On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).

View on SEC.gov

HAEMONETICS CORP filing history →

Source: SEC EDGAR

accession 0000313143-26-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.